Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986515 in Severe, Refractory Autoimmune Diseases
NCT07115745Phase 1Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2025
- Primary completion
- Mar 2029
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 10
01
Overview
Phase 1, open-label, single-arm trial of BMS-986515 in systemic lupus erythematosus (SLE), inflammatory myopathy (IIM), systemic sclerosis (SSc) and 1 more, sponsored by Bristol Myers Squibb. Primary endpoints: Treatment-Emergent Adverse Events at 24 months, Serious Adverse Events at 24 months and 4 more. Started Sep 2025; status: recruiting.
02
Drugs
BMS-986515
03
Conditions
systemic lupus erythematosus (SLE)inflammatory myopathy (IIM)systemic sclerosis (SSc)rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT07115745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07115745.